权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mentorship in research on opioid use disorder, HIV and marginalized populations

指导阿片类药物使用障碍、艾滋病毒和边缘化人群的研究

基本信息

批准号：
10619044
负责人：
Aaron D Fox
金额：
$ 18.48万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-15 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10619044
关键词：
AIDS prevention Acquired Immunodeficiency Syndrome Advertisements Advisory Committees Area Award Baseline Surveys Behavior Black Populations Black race Buprenorphine COVID-19 Characteristics Client Clinic Clinical Clinical Investigator Clinical Research Clinical Treatment Clinical Trials Collaborations Complement County Data Dedications Diagnostic Reagent Kits Disease Outbreaks Dose Education Effectiveness Emergency Situation Enrollment Environment Equipment Exclusion Face Facebook Frequencies Fright Future Geographic Locations Geography Goals Grant Guidelines HIV HIV Infections HIV risk Harm Reduction Health Policy Helping to End Addiction Long-term Hepatitis C Transmission Hepatitis C virus Home Hospitalization Hospitals Hour Human immunodeficiency virus test Imprisonment Individual Informed Consent Injecting drug user Injections Internet Intervention Latinx Latinx population Law Enforcement Laws Leadership Link Longitudinal cohort study Measures Mediating Medical Medical center Medicine Mentors Mentorship Mid-Career Clinical Scientist Award (K24)Modeling Naloxone Needle-Exchange Programs Overdose Participant Persons Pharmaceutical Preparations Pharmacy facility Physicians Policies Population Prevalence Prevention Measures Prevention Research Primary Care Principal Investigator Privacy Procedures Public Health Puerto Rico Questionnaires Randomized, Controlled Trials Research Research Methodology Research Personnel Resources Risk Risk Assessment Risk Behaviors Rural Safety Sampling Scientist Secure Self Administration Services Source Sterility Surveys Syringes Talents Technology Test Result Testing Time Training Translating Translational Research Transportation Twitter Underserved Population United States United States National Institutes of Health Woman Youth addiction buprenorphine treatment career career development chronic pain chronic pain patient cohort college cost effectiveness efficacy testing eligible participant evidence base experience feasibility testing follow-up high risk housing instability injection drug use innovation marginalized population member mid-career faculty multidisciplinary novel opioid epidemic opioid use disorder overdose risk participant enrollment patient oriented research peer support prevention service primary outcome programs recruit satisfaction screening service uptake skills social social media social stigma sociodemographics uptake urban setting web platform web site

项目摘要

Mentorship in research on opioid use disorder, HIV and marginalized populations People who inject drugs (PWID) are at high risk for overdose and increasing HIV risk, yet they sub-optimally receive evidence-based opioid use disorder (OUD) treatment and HIV prevention measures. Engaging PWID and persons with OUD from marginalized groups requires innovative approaches. Aaron D. Fox, MD MS is an Addiction Medicine physician and Associate Professor of Medicine at Albert Einstein College of Medicine- Montefiore Medical Center. He is an experienced research mentor, the director of the Bronx Transitions Clinic, which provides a medical home to formerly incarcerated individuals, and the principal investigator of two clinical trials of innovative buprenorphine treatment interventions (see below). Einstein-Montefiore’s Institute for Clinical and Translational Research, and the Einstein-Rockefeller-CUNY Center for AIDS Research, provide an outstanding environment for supporting early-stage investigators and trainees. As part of the NIH HEAL initiative, Einstein-Montefiore was recently awarded one of four IMPOWR grants to develop a research center on chronic pain and OUD. In this K24 mid-career mentorship award, Dr. Fox proposes to capitalize upon these resources in mentoring six talented early-stage investigators in research on OUD, HIV, and marginalized populations. Dr. Fox would also gain skills in mentoring, new research methods, and drug policy leadership with the following career development objectives: 1) To provide outstanding mentorship to diverse early-stage investigators who will develop independent research careers in OUD treatment and HIV prevention; 2) To gain skills in internet-mediated HIV prevention research; and 3) To translate evidence into clinical guidelines and policy regarding access to addiction treatment and HIV prevention services. To meet these objectives, Dr. Fox will convene an advisory team with expertise in mentoring, internet-mediated research, and drug policy, while participating in training specific to research mentoring and health policy leadership. Dr. Fox’s current studies provide a unique environment where early-stage investigators can participate in patient-oriented research in primary care, hospitals, syringe services programs, and a post-incarceration “transitions clinic.” Dr. Fox leads two large randomized controlled trials: buprenorphine microdose inductions for hospitalized patients with chronic pain (RM1DA055437), and the effectiveness, safety, and cost-effectiveness of buprenorphine treatment initiation at syringe services programs (R01DA044878). This application also proposes new internet- mediated HIV prevention research in collaboration with NEXT Distro, the first formal internet-based mail delivery syringe services program in the United States. These studies will serve as a platform for trainees to develop careers in patient-oriented research that is highly relevant for drug policy and clinical guidelines. Completion of the proposed K24 award would advance research in OUD treatment and HIV prevention, while also expanding and diversifying the research workforce dedicated to OUD, HIV, and marginalized populations.

指导阿片类药物使用障碍、艾滋病毒和边缘化人群的研究